Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Nucl Med ; 49(9): 1520-8, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18703595

ABSTRACT

UNLABELLED: Clinical molecular imaging of apoptosis is a highly desirable yet unmet challenge. Here we provide the first report on (18)F-labeled 5-fluoropentyl-2-methyl-malonic acid ((18)F-ML-10), a small-molecule, (18)F-labeled PET tracer for the imaging of apoptosis in vivo; this report includes descriptions of the synthesis, radiolabeling, and biodistribution of this novel apoptosis marker. We also describe the use of (18)F-ML-10 for small-animal PET of neurovascular cell death in experimental cerebral stroke in mice. METHODS: (18)F-ML-10 was synthesized by nucleophilic substitution from the respective mesylate precursor, and its biodistribution was assessed in healthy rats. Permanent occlusion of the middle cerebral artery (MCA) was induced in mice, and small-animal PET was performed 24 h later. RESULTS: Efficient radiolabeling of ML-10 with (18)F was achieved. Biodistribution studies with (18)F-ML-10 revealed rapid clearance from blood (half-life of 23 min), a lack of binding to healthy tissues, and rapid elimination through the kidneys. No significant tracer metabolism in vivo was observed. Clear images of distinct regions of increased uptake, selectively in the ischemic MCA territory, were obtained in the in vivo small-animal PET studies. Uptake measurements ex vivo revealed 2-fold-higher uptake in the affected hemisphere and 6- to 10-fold-higher uptake in the region of interest of the infarct. The cerebral uptake of (18)F-ML-10 was well correlated with histologic evidence of cell death. The tracer was retained in the stroke area but was cleared from blood and from intact brain areas. CONCLUSION: (18)F-ML-10 is useful for noninvasive PET of neurovascular histopathology in ischemic cerebral stroke in vivo. Such an assessment may assist in characterization of the extent of stroke-related cerebral damage and in the monitoring of disease course and effect of treatment.


Subject(s)
Apoptosis , Methylmalonic Acid/analogs & derivatives , Molecular Probe Techniques , Neurons/diagnostic imaging , Neurons/metabolism , Positron-Emission Tomography/methods , Stroke/diagnostic imaging , Stroke/metabolism , Animals , Disease Models, Animal , Male , Methylmalonic Acid/pharmacokinetics , Radiopharmaceuticals/pharmacokinetics , Rats , Stroke/pathology
2.
Chem Biol Drug Des ; 67(2): 127-36, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16492160

ABSTRACT

Somatostatin owes its biological activity to the presence of a well-defined beta-turn centered around the tetrapeptide Phe-Trp-Lys-Thr. We have developed a light-activated beta-turn scaffold, 1, with the ability to template a beta-turn conformation within the somatostatin tetrapeptide only upon photolysis. The three-dimensional structure of the trans cyclic peptide I obtained by NMR revealed no beta-turn conformation; however, when isomerized to the cis form II with light, the solution structure of the resulting cyclic peptide was found to contain a type II' beta-turn within the Phe-Trp-Lys-Thr sequence. Binding assays with the SRIF receptor demonstrated that the cis peptide displayed enhanced affinity for the receptor over the trans form.


Subject(s)
Oligopeptides/chemistry , Receptors, Somatostatin/agonists , Somatostatin/chemistry , Animals , Cell Line , Isomerism , Light , Mice , Nuclear Magnetic Resonance, Biomolecular/methods , Oligopeptides/chemical synthesis , Oligopeptides/pharmacology , Protein Binding , Protein Structure, Secondary/radiation effects , Receptors, Somatostatin/metabolism , Somatostatin/chemical synthesis , Somatostatin/pharmacology , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...